Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Int J Urol

Retrieve available abstracts of 59 articles:
HTML format
Text format



Single Articles


    May 2017
  1. MITSUZUKA K
    Editorial comment to Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
    Int J Urol. 2017 May 21. doi: 10.1111/iju.13379.
    PubMed     Text format    


    April 2017
  2. TERADA N, Maughan BL, Akamatsu S, Kobayashi T, et al
    Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
    Int J Urol. 2017 Apr 28. doi: 10.1111/iju.13346.
    PubMed     Text format     Abstract available


  3. OKIHARA K, Yorozu A, Saito S, Tanaka N, et al
    Assessment of sexual function in Japanese men with prostate cancer undergoing permanent brachytherapy without androgen deprivation therapy: Analysis from the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation database.
    Int J Urol. 2017 Apr 28. doi: 10.1111/iju.13358.
    PubMed     Text format     Abstract available


    March 2017
  4. NARAYAN VM, Konety BR, Warlick C
    Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice.
    Int J Urol. 2017 Mar 27. doi: 10.1111/iju.13326.
    PubMed     Text format     Abstract available


    February 2017
  5. SHOJI S, Hiraiwa S, Ogawa T, Kawakami M, et al
    Accuracy of real-time magnetic resonance imaging-transrectal ultrasound fusion image-guided transperineal target biopsy with needle tracking with a mechanical position-encoded stepper in detecting significant prostate cancer in biopsy-naive men.
    Int J Urol. 2017 Feb 21. doi: 10.1111/iju.13306.
    PubMed     Text format     Abstract available


  6. EGEVAD L, Samaratunga H, Delahunt B
    Editorial Comment to Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam.
    Int J Urol. 2017 Feb 17. doi: 10.1111/iju.13305.
    PubMed     Text format    


  7. ALBERTS AR, Bokhorst LP, Kweldam CF, Schoots IG, et al
    Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam.
    Int J Urol. 2017 Feb 7. doi: 10.1111/iju.13294.
    PubMed     Text format     Abstract available


    January 2017
  8. KESCH C, Hadaschik BA, Radtke JP
    Editorial Comment to Assessing clinically significant prostate cancer: Diagnostic properties of multiparametric magnetic resonance imaging compared to three-dimensional transperineal template mapping histopathology.
    Int J Urol. 2017 Jan 13. doi: 10.1111/iju.13263.
    PubMed     Text format    


    December 2016
  9. FENG T, Howard LE, Vidal AC, Moreira DM, et al
    Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study.
    Int J Urol. 2016 Dec 22. doi: 10.1111/iju.13265.
    PubMed     Text format     Abstract available


    November 2016
  10. JAZAYERI SB, Samadi DB
    Prostate cancer in African Americans: Early oncological and functional outcomes after robotic prostatectomy.
    Int J Urol. 2016 Nov 16. doi: 10.1111/iju.13255.
    PubMed     Text format    


  11. TSIVIAN M, Gupta RT, Tsivian E, Qi P, et al
    Assessing clinically significant prostate cancer: Diagnostic properties of multiparametric magnetic resonance imaging compared to three-dimensional transperineal template mapping histopathology.
    Int J Urol. 2016 Nov 8. doi: 10.1111/iju.13251.
    PubMed     Text format     Abstract available


    October 2016
  12. RAMALINGAM S, Eisenberg A, Foo WC, Freedman J, et al
    Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome.
    Int J Urol. 2016 Oct 21. doi: 10.1111/iju.13225.
    PubMed     Text format     Abstract available


  13. KRETSCHMER A, Gratzke C
    Editorial Comment to Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome.
    Int J Urol. 2016 Oct 18. doi: 10.1111/iju.13239.
    PubMed     Text format    


  14. HENNING JD, Bonachea LA, Bunker CH, Patrick AL, et al
    Human herpesvirus 8 infection contributes to a T helper 2 immune response in men from Tobago with prostate cancer.
    Int J Urol. 2016 Oct 12. doi: 10.1111/iju.13243.
    PubMed     Text format     Abstract available


    September 2016
  15. OSAWA T, Wittmann D, Jimbo M, Keller ET, et al
    Providing prostate cancer survivorship care in Japan: Implications from the USA care model.
    Int J Urol. 2016 Sep 13. doi: 10.1111/iju.13186.
    PubMed     Text format     Abstract available


  16. SCHIAVINA R, Bianchi L, Borghesi M, Briganti A, et al
    Predicting survival in node-positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multi-institutional database.
    Int J Urol. 2016 Sep 12. doi: 10.1111/iju.13203.
    PubMed     Text format     Abstract available


    July 2016
  17. LIU CM, Hsieh CL, Shen CN, Lin CC, et al
    Exosomes from the tumor microenvironment as reciprocal regulators that enhance prostate cancer progression.
    Int J Urol. 2016 Jul 10. doi: 10.1111/iju.13145.
    PubMed     Text format     Abstract available


    June 2016
  18. PARIMI S, Chi KN
    Chemotherapy for metastatic castration-sensitive prostate cancer.
    Int J Urol. 2016 Jun 26. doi: 10.1111/iju.13148.
    PubMed     Text format     Abstract available


  19. SAKAMOTO S
    Editorial Comment to Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.
    Int J Urol. 2016 Jun 20. doi: 10.1111/iju.13147.
    PubMed     Text format    


  20. SAKAMOTO S
    Editorial Comment to Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.
    Int J Urol. 2016 Jun 20. doi: 10.1111/iju.13146.
    PubMed     Text format    


  21. IMAMURA Y, Sadar MD
    Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.
    Int J Urol. 2016 Jun 14. doi: 10.1111/iju.13137.
    PubMed     Text format     Abstract available


  22. PORPIGLIA F, Cantiello F, De Luca S, De Pascale A, et al
    Multiparametric magnetic resonance imaging and active surveillance: How to better select insignificant prostate cancer?
    Int J Urol. 2016 Jun 9. doi: 10.1111/iju.13138.
    PubMed     Text format     Abstract available


  23. BRYCE AH, Antonarakis ES
    Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.
    Int J Urol. 2016 Jun 3. doi: 10.1111/iju.13134.
    PubMed     Text format     Abstract available


    May 2016
  24. UENO Y, Tamada T, Bist V, Reinhold C, et al
    Multiparametric magnetic resonance imaging: Current role in prostate cancer management.
    Int J Urol. 2016 May 17. doi: 10.1111/iju.13119.
    PubMed     Text format     Abstract available


    April 2016
  25. SAKAMOTO S
    Editorial Comment to Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.
    Int J Urol. 2016 Apr 17. doi: 10.1111/iju.13090.
    PubMed     Text format    


  26. SHIOTA M, Eto M
    Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.
    Int J Urol. 2016 Apr 8. doi: 10.1111/iju.13091.
    PubMed     Text format     Abstract available


  27. MITSUZUKA K
    Editorial Comment to Prediagnostic prostate-specific antigen kinetics and the risk of biopsy progression in active surveillance patients.
    Int J Urol. 2016;23:317-8.
    PubMed     Text format    


  28. IREMASHVILI V, Barney SL, Manoharan M, Kava BR, et al
    Prediagnostic prostate-specific antigen kinetics and the risk of biopsy progression in active surveillance patients.
    Int J Urol. 2016;23:313-7.
    PubMed     Text format     Abstract available


    March 2016
  29. KIMURA G, Yonese J, Fukagai T, Kamba T, et al
    Enzalutamide in Japanese patients with chemotherapy-naive, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial.
    Int J Urol. 2016 Mar 27. doi: 10.1111/iju.13072.
    PubMed     Text format     Abstract available


  30. MCGINLEY KF, Sun X, Howard LE, Aronson WJ, et al
    Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database.
    Int J Urol. 2016;23:241-6.
    PubMed     Text format     Abstract available


    February 2016
  31. SUN Y, Zou Q, Sun Z, Li C, et al
    Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.
    Int J Urol. 2016 Feb 15. doi: 10.1111/iju.13051.
    PubMed     Text format     Abstract available


  32. BIRKELAND S
    Re: Prostate-specific antigen-based prostate cancer screening: Past and future.
    Int J Urol. 2016 Feb 2. doi: 10.1111/iju.13038.
    PubMed     Text format    


    January 2016
  33. GANDAGLIA G, Montorsi F, Briganti A
    Editorial Comment to Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer.
    Int J Urol. 2016 Jan 20. doi: 10.1111/iju.13046.
    PubMed     Text format    


  34. SCHMID M, Hanske J, Ravi P, Krishna N, et al
    Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer.
    Int J Urol. 2016 Jan 13. doi: 10.1111/iju.13043.
    PubMed     Text format     Abstract available


  35. SONG W, Jeon HG, Sung HH, Jeong BC, et al
    Prognostic factors after salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy.
    Int J Urol. 2016;23:56-61.
    PubMed     Text format     Abstract available


    December 2015
  36. MATSUSHIMA M, Kikuchi E, Matsumoto K, Kosaka T, et al
    Erectile function status is highly associated with prostate-specific antigen bounce in localized prostate cancer patients treated with permanent prostate brachytherapy.
    Int J Urol. 2015 Dec 12. doi: 10.1111/iju.13029.
    PubMed     Text format     Abstract available


    November 2015
  37. ROMERO-OTERO J, Garcia-Gomez B, Duarte-Ojeda JM, Rodriguez-Antolin A, et al
    Active surveillance for prostate cancer.
    Int J Urol. 2015 Nov 30. doi: 10.1111/iju.13016.
    PubMed     Text format     Abstract available


    August 2015
  38. HISASUE SI
    Contemporary perspective and management of testosterone deficiency: Modifiable factors and variable management.
    Int J Urol. 2015 Aug 25. doi: 10.1111/iju.12880.
    PubMed     Text format     Abstract available


    May 2015
  39. SCHIFFMANN J, Beyer B, Tennstedt P, Boehm K, et al
    Oncological outcome after radical prostatectomy: Marital status does not make a difference.
    Int J Urol. 2015;22:484-9.
    PubMed     Text format     Abstract available


  40. SKARECKY D
    Editorial Comment from Mr Skarecky to Comparative investigation on clinical outcomes of robot-assisted radical prostatectomy between experienced open prostatic surgeons and novice open surgeons in a laparoscopically naive center with a limited caseloa
    Int J Urol. 2015;22:476.
    PubMed     Text format    


  41. SHIROKI R
    Editorial Comment from Dr Shiroki to Comparative investigation on clinical outcomes of robot-assisted radical prostatectomy between experienced open prostatic surgeons and novice open surgeons in a laparoscopically naive center with a limited caseload
    Int J Urol. 2015;22:475.
    PubMed     Text format    


  42. SUMITOMO M, Kanao K, Kato Y, Yoshizawa T, et al
    Comparative investigation on clinical outcomes of robot-assisted radical prostatectomy between experienced open prostatic surgeons and novice open surgeons in a laparoscopically naive center with a limited caseload.
    Int J Urol. 2015;22:469-74.
    PubMed     Text format     Abstract available


    April 2015
  43. SATO YT
    Editorial comment to Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital d
    Int J Urol. 2015;22:366-7.
    PubMed     Text format    


  44. MITHAL P, Howard LE, Aronson WJ, Kane CJ, et al
    Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Int J Urol. 2015;22:362-6.
    PubMed     Text format     Abstract available


    March 2015
  45. ROEHRBORN CG, Casabe A, Glina S, Sorsaburu S, et al
    Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study compari
    Int J Urol. 2015 Mar 31. doi: 10.1111/iju.12741.
    PubMed     Text format     Abstract available


  46. ETO M
    IJU this issue.
    Int J Urol. 2015;22:241.
    PubMed     Text format    


  47. NAMIKI S
    Editorial comment to International Prostate Symptom Score is a predictive factor of lower urinary tract symptoms after radical prostatectomy.
    Int J Urol. 2015;22:287.
    PubMed     Text format    


  48. BAYOUD Y, de la Taille A, Ouzzane A, Ploussard G, et al
    International Prostate Symptom Score is a predictive factor of lower urinary tract symptoms after radical prostatectomy.
    Int J Urol. 2015;22:283-7.
    PubMed     Text format     Abstract available


  49. YUMIOKA T, Iwamoto H, Masago T, Morizane S, et al
    Robot-assisted radical prostatectomy in an initial Japanese series: the impact of prior abdominal surgery on surgical outcomes.
    Int J Urol. 2015;22:278-82.
    PubMed     Text format     Abstract available


  50. MATSUYAMA H, Matsumoto H, Nagao K, Harada N, et al
    Running suture versus interrupted suture for vesicourethral anastomosis in retropubic radical prostatectomy: a randomized study.
    Int J Urol. 2015;22:271-7.
    PubMed     Text format     Abstract available


    February 2015
  51. EGAWA S
    IJU this issue.
    Int J Urol. 2015;22:139.
    PubMed     Text format    


  52. SIVARAMAN A, Sanchez-Salas R, Barret E, Ahallal Y, et al
    Transperineal template-guided mapping biopsy of the prostate.
    Int J Urol. 2015;22:146-51.
    PubMed     Text format     Abstract available


  53. TSUZUKI T
    Intraductal carcinoma of the prostate: a comprehensive and updated review.
    Int J Urol. 2015;22:140-5.
    PubMed     Text format     Abstract available


  54. HASHIMOTO T, Yoshioka K, Nagao G, Nakagami Y, et al
    Prediction of biochemical recurrence after robot-assisted radical prostatectomy: analysis of 784 Japanese patients.
    Int J Urol. 2015;22:188-93.
    PubMed     Text format     Abstract available


  55. SHOJI S, Hiraiwa S, Endo J, Hashida K, et al
    Manually controlled targeted prostate biopsy with real-time fusion imaging of multiparametric magnetic resonance imaging and transrectal ultrasound: an early experience.
    Int J Urol. 2015;22:173-8.
    PubMed     Text format     Abstract available


  56. SHOJI S
    Response to editorial comment to Manually controlled targeted prostate biopsy with real-time fusion imaging of multiparametric magnetic resonance imaging and transrectal ultrasound: an early experience.
    Int J Urol. 2015;22:179-80.
    PubMed     Text format    


  57. TELONIS D, Mouraviev V
    Editorial comment to Manually controlled targeted prostate biopsy with real-time fusion imaging of multiparametric magnetic resonance imaging and transrectal ultrasound: an early experience.
    Int J Urol. 2015;22:178-9.
    PubMed     Text format    


  58. SHIMBO M
    Editorial comment to Prediction of biochemical recurrence after robot-assisted radical prostatectomy: analysis of 784 Japanese patients.
    Int J Urol. 2015;22:193-4.
    PubMed     Text format    


  59. MITSUZUKA K
    Editorial comment to Transperineal template-guided mapping biopsy of the prostate.
    Int J Urol. 2015;22:152.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: